Navigation Links
InNexus Biotechnology CEO to Present at BioContactQuebec 2008
Date:9/29/2008

-- Receives Recognition in Two Leading Industry Publications --

BRITISH COLUMBIA, Canada, Sept. 29 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces Jeff Morhet, CEO and Chairman, to present during BioContactQuebec 2008. The company also announces the featuring of Mr. Morhet in two leading publications, Genetic Engineering & Biotechnology News and The PharmaVoice List of Top 100 in Life Sciences.

During BioContactQuebec 2008, InNexus' CEO will present on Thursday, October 2nd at 2:30-3:00 PM EDT on the Salle Laval at the Chateau Frontenac, Quebec. The presentation will include a company overview and information about InNexus' unique business strategy, its DXL(TM) technology platform and upcoming company milestones. Investors, venture capitalists, company executives, scientists and other industry leaders will attend the symposium.

Also announced, the most recent edition of Genetic Engineering & Biotechnology News features InNexus CEO Morhet in the article, Peptide Drugs Becoming More Prevalent, where he discusses the pharmaceutical industry and outlines InNexus' DXL(TM) antibody enhancement technology platform. http://www.genengnews.com/articles/chitem.aspx?aid=2580.

The company also announced Mr. Morhet has also been named to PharmaVOICE's list of the "100 Most Inspiring People in the Life Sciences", July/August Edition. The publication illustrates those individuals who think outside the box, pioneering new paths to success and inspire their colleagues in the industry. http://www.pharmavoice.com

About BioContactQuebec 2008

BioContactQuebec 2008 is a biopharmaceutical partnership symposium gathering over 1200 participants and more than 150 biopharmaceutical companies, coming from Canada, the United States, Asia and Europe, presenting in different sectors of activities (diagnostics, therapeutics and services) and disciplines such as cancer, immunology and inflammation.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in- house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit http://www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control that may cause actual results or performance to differ materially from those currently anticipated in such statements.


'/>"/>
SOURCE InNexus Biotechnology Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. St. Josephs Hospital and InNexus Biotechnology Enter Collaborative Partnership
2. InNexus Biotechnology Strengthens Patent Team With New Leadership
3. InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
6. Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
7. Alexions Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product
8. Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
9. New Report on 633 Biotechnology Medicines Under Development Released in Michigan
10. Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc.
11. Long-Term Investments Remain Critical to Biotechnology Industry Growth, According to a New Report by Global Industry Analysts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... 2016 , ... WEDI, the nation’s leading authority on the use of health ... has been named by the WEDI Board of Directors as WEDI’s president and CEO. ... with more than 35 years of experience in healthcare, association management and organizational leadership, ...
(Date:5/24/2016)... ... May 24, 2016 , ... Cell therapies for a ... accelerated by research at Worcester Polytechnic Institute (WPI) that yielded a newly patented ... regeneration. , The novel method, developed by WPI faculty members Raymond Page, PhD, ...
(Date:5/24/2016)... Rockville, Maryland (PRWEB) , ... May 24, 2016 ... ... introduction of a newly re-branded identity. The new Media Cybernetics corporate branding reflects ... the world of imaging and image analysis. The re-branding components include a crisp, ...
(Date:5/23/2016)... Ind. , May 23, 2016 Zimmer Biomet ... musculoskeletal healthcare, today announced that its Board of Directors has ... for the second quarter of 2016. The ... or about July 29, 2016 to stockholders of record as ... declarations of dividends are subject to approval of the Board ...
Breaking Biology Technology:
(Date:3/15/2016)... 2016 Yissum Research Development Company of ... of the Hebrew University, announced today the formation of ... of various human biological indicators. Neteera Technologies has completed ... private investors. ... of electromagnetic emissions from sweat ducts, enables reliable and ...
(Date:3/11/2016)... http://www.apimages.com ) - --> http://www.apimages.com ) - ... ( http://www.apimages.com ) - Germany . The ... refugee identity cards. DERMALOG will be unveiling this device, and a ... next week.   --> Germany . ... new refugee identity cards. DERMALOG will be unveiling this device, and ...
(Date:3/10/2016)... 2016   Unisys Corporation (NYSE: UIS ) ... (CBP) is testing its biometric identity solution at the Otay ... to help identify certain non-U.S. citizens leaving the country. ... to help determine the efficiency and accuracy of using biometric ... will run until May 2016. --> the ...
Breaking Biology News(10 mins):